China Resources Boya Bio-Pharmaceutical Co., Ltd. (300294)

Overview

China Resources Boya Bio-pharmaceutical Group Co., Ltd., originally known as Boya Bio-pharmaceutical Group Co., Ltd., operates within the blood product sector in China. Founded in 1993 and headquartered in Fuzhou City, China, the company has expanded its scope to include not only blood products but also non-blood products and various pharmaceuticals. Engaged in the research, development, production, and sales of medical solutions, it caters to a wide range of health conditions, including anti-infective, diabetes, cardiovascular and cerebrovascular diseases. Moreover, China Resources Boya Bio-pharmaceutical Group has a distribution arm for its blood products, indicating its integrated approach in the pharmaceutical industry.

Products and Services

The company's product lineup is diverse, covering both blood and non-blood products alongside a strong emphasis on pharmaceuticals to address multiple healthcare needs.

• Blood Products: This category includes vital components such as human coagulation factors, human prothrombin complex, human fibrinogen, human albumin, intravenous human immunoglobulin, and rabies immunoglobulin. These products are essential for treating various conditions like coagulation disorders, immune deficiencies, and post-exposure rabies prophylaxis.
• Non-Blood Products: Within this range, the company offers products such as bone polypeptide, oxytocin, heparin sodium, and posterior pituitary injection. These cater to a variety of medical needs, from osteoporosis treatment to labor induction, anticoagulation, and pituitary gland hormone therapy.
• Pharmaceuticals: Their pharmaceutical offerings encompass a broad spectrum of treatments. These include:
  • Metformin Hydrochloride Enteric-Coated Tablets: Aimed at managing type 2 diabetes, these tablets help improve blood sugar control.
  • Glimepiride Tablets: Another type 2 diabetes treatment that helps increase insulin release from the pancreas.
  • Calcium Dobesilate Products: Used for treating diabetic retinopathy and chronic venous insufficiency.
  • Pioglitazone Hydrochloride Dispersible Tablets: These tablets are also used in the management of type 2 diabetes, working to decrease insulin resistance.
• Research and Development: Beyond its product offerings, the company is deeply involved in the research, development, production, and sales of new treatments in the areas of anti-infective, diabetes, cardiovascular, and cerebrovascular diseases. This commitment to innovation ensures the continuous evolution and expansion of their product portfolio to meet emerging health challenges.
• Distribution of Blood Products: Besides manufacturing, China Resources Boya Bio-pharmaceutical Group also focuses on the distribution of blood products. This element of their business model highlights their role not just as a producer but also as a key distributor within China's pharmaceutical and healthcare sector.